Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$17.83−0.35 (-1.93%)
Close on Nov 18, 2026Market cap $1.10BP/E –Yield –
Vor Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vor Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$177.42M. For fiscal 2025 it was -$371.64M. The highest annual figure on record is -$43.37M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$371.64M | – |
| FY2024 | Dec 31, 2024 | -$121.19M | – |
| FY2023 | Dec 31, 2023 | -$126.04M | – |
| FY2022 | Dec 31, 2022 | -$93.42M | – |
| FY2021 | Dec 31, 2021 | -$69.02M | – |
| FY2020 | Dec 31, 2020 | -$43.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$58.44M | – |
| Q2 FY2026 | Jun 30, 2026 | -$47.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$35.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$274.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.73M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.79M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.88M | – |
See a number that looks wrong?